TAPAN M. KADIA, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas M0120
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about TAPAN M. KADIA at radaris.comName
Address
Phone
5102 Evergreen St, Bellaire, TX 77401
1535 Ken Garden Dr, Houston, TX 77047
1535 Kew Garden Dr, Houston, TX 77047
8181 Fannin St, Houston, TX 77054
Houston, TX
Professional information
Dr. Tapan M Kadia, Houston TX - MD (Doctor of Medicine)
Age:
48
Address:
Houston Office
1515 Holcombe Blvd SUITE 10, Houston 77030
(877) 632-6789 (Phone)
1515 Holcombe Blvd, Houston 77030
1515 Holcombe Blvd SUITE 207, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
(713) 792-2121 (Phone)
1515 Holcombe Blvd SUITE 10, Houston 77030
(877) 632-6789 (Phone)
1515 Holcombe Blvd, Houston 77030
1515 Holcombe Blvd SUITE 207, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
(713) 792-2121 (Phone)
Hospitals:
Houston Office
1515 Holcombe Blvd SUITE 10, Houston 77030
1515 Holcombe Blvd, Houston 77030
1515 Holcombe Blvd SUITE 207, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
1515 Holcombe Blvd SUITE 10, Houston 77030
1515 Holcombe Blvd, Houston 77030
1515 Holcombe Blvd SUITE 207, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
Education:
Medical Schools
Umdnj-Robt W Johnson Med Sch
Graduated: 2001
Umdnj-Robt W Johnson Med Sch
Graduated: 2001
Physician At Md Anderson Cancer Center
Position:
Assistant Professor at MD Anderson Cancer Center
Location:
Houston, Texas Area
Industry:
Medical Practice
Work:
MD Anderson Cancer Center
since Jul 2005
-
Assistant Professor
Baylor College of Medicine
2004 - 2005
-
Chief Resident
Education:
University of Medicine and Dentistry of New Jersey -Robert Wood Johnson Medical School 1997 - 2001
MD, Medicine Rutgers, The State University of New Jersey-New Brunswick 1994 - 1998
Stuyvesant High School 1990 - 1994
MD, Medicine Rutgers, The State University of New Jersey-New Brunswick 1994 - 1998
Stuyvesant High School 1990 - 1994
Tapan Mahendra Kadia, Houston TX
Specialties:
Internist
Address:
1515 Holcombe Blvd, Houston, TX 77030
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Tapan M Kadia, Houston TX
Specialties:
Internal Medicine, Hematology, Medical Oncology, Hematology & Oncology
Work:
M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
UMDNJ Robert Wood Johnson (2001)
Methods For Treating Cancer
US Patent:
2013021, Aug 22, 2013
Filed:
Nov 4, 2011
Appl. No.:
13/883374
Inventors:
Gautam Borthakur - Houston TX, US
Tapan M. Kadia - Houston TX, US
Hagop M. Kantarjian - Houston TX, US
Sylvie Laquerre - King of Prussia PA, US
Tapan M. Kadia - Houston TX, US
Hagop M. Kantarjian - Houston TX, US
Sylvie Laquerre - King of Prussia PA, US
Assignee:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED - Brentford
International Classification:
A61K 31/519, A61K 31/436, A61K 45/06, A61K 31/506
US Classification:
5142641
Abstract:
Methods are provided for treating a human having cancer comprising detecting at least one mutation in a Ras protein or a gene encoding at least one Ras protein from at least one tumor cell from said human and treating said human having at least one mutation in at least one Ras protein or a gene encoding at least one Ras protein with a pharmaceutical composition comprising at least one MEK inhibitor comprising a compound of Structure (I):or a pharmaceutically acceptable salt or solvate thereof.